Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study to Compare Haplo-identical HSCT Versus Chemotherapy in First Remission for Standard-risk Adult Acute Lymphoblastic Leukemia

NCT02042690 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT02042690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02042690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study to Compare Haplo-identical HSCT Versus Chemotherapy in First Remission for Standard-risk Adult Acute Lymphoblastic Leukemia
Lead sponsor
Peking University
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2014
Completion date
April 30, 2019
Enrollment
131 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia